Needham & Company LLC restated their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research report released on Monday, December 23rd, AnalystRatings.com reports. The brokerage currently has a $84.00 target price on the stock.

Other equities research analysts have also issued reports about the company. Oppenheimer upped their price objective on Crispr Therapeutics from $65.00 to $80.00 and gave the company an outperform rating in a research note on Monday, November 25th. Roth Capital boosted their target price on shares of Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Goldman Sachs Group upped their price target on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a neutral rating in a research note on Tuesday, November 19th. Wells Fargo & Co reaffirmed a buy rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. Finally, BidaskClub downgraded shares of Crispr Therapeutics from a strong-buy rating to a buy rating in a research note on Friday, December 13th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $71.38.

CRSP stock traded down $1.30 on Monday, reaching $58.33. 1,116,590 shares of the company’s stock were exchanged, compared to its average volume of 1,136,865. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm has a market cap of $3.29 billion, a PE ratio of -16.96 and a beta of 3.20. Crispr Therapeutics has a twelve month low of $29.34 and a twelve month high of $74.00. The stock has a fifty day moving average of $65.34 and a 200-day moving average of $52.09.

Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The company had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. On average, equities research analysts predict that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.

In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total transaction of $412,500.00. Following the transaction, the director now owns 7,500 shares in the company, valued at $412,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock worth $3,620,760 in the last quarter. Company insiders own 21.40% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of CRSP. Benjamin Edwards Inc. grew its position in shares of Crispr Therapeutics by 96.4% during the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after buying an additional 268 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Crispr Therapeutics by 13.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock valued at $118,000 after purchasing an additional 343 shares during the period. Traynor Capital Management Inc. grew its position in Crispr Therapeutics by 5.8% during the 3rd quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock worth $280,000 after acquiring an additional 375 shares during the last quarter. Commonwealth Equity Services LLC grew its position in Crispr Therapeutics by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock worth $746,000 after acquiring an additional 386 shares during the last quarter. Finally, Farmers & Merchants Trust Co of Chambersburg PA bought a new stake in Crispr Therapeutics during the 4th quarter worth approximately $26,000. Hedge funds and other institutional investors own 49.82% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

See Also: How to Invest in an Index Fund

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link